肾去神经术：是否已准备好投入实际应用？
Renal Denervation: Is It Ready for Prime Time?
机构信息
Klinik für Innere Medizin III, Kardiologie, Angiologie, Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Saarland University Medical Center and Saarland University, 66421, Homburg, Saar, Germany.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
出版信息
Curr Cardiol Rep. 2019 Jul 5;21(8):80. doi: 10.1007/s11886-019-1164-2.
PURPOSE OF REVIEW
Interventional cardiology and in particular the field of renal denervation is subject to constant change. This review provides an up to date overview of renal denervation trials and an outlook on what to expect in the future.
RECENT FINDINGS
After the sham-controlled SYMPLICITY HTN-3 trial dampened the euphoria following early renal denervation trials, the recently published results of the sham-controlled SPYRAL HTN and RADIANCE HTN trials provided proof-of-principle for the blood pressure-lowering efficacy of renal denervation. However, these studies underline the major issue of patients' non-adherence to antihypertensive medication as well as the need for reliable patient- and procedure-related predictors of response. The second generation of sham-controlled renal denervation trials provided proof of principle for the blood pressure-lowering efficacy of RDN. However, larger trials have to assess long-term safety and efficacy.
目的综述
介入心脏病学，尤其是肾去神经术领域，不断变化。本文对肾去神经术试验进行了最新综述，并对未来的发展进行了展望。
最近的发现
在假手术对照的 SYMPLICITY HTN-3 试验降低了早期肾去神经术试验的兴奋之后，最近公布的假手术对照 SPYRAL HTN 和 RADIANCE HTN 试验的结果为肾去神经术降低血压的疗效提供了原理证明。然而，这些研究强调了患者不遵守抗高血压药物治疗的主要问题，以及对可靠的与患者和程序相关的反应预测因素的需求。第二代假手术对照的肾去神经术试验为 RDN 的降压疗效提供了原理证明。然而，还需要更大规模的试验来评估长期安全性和疗效。
Zotero 插件